The company's main focus is on two diseases: cognitive disorders associated with Down syndrome and Alzheimer's disease, as well as hearing loss induced by ototoxic products. Perha Pharma is developing innovative, low molecular weight kinase inhibitors to prevent cisplatin-induced hearing loss and correct cognitive impairments in mouse models of DS and rodent models of AD. Their preclinical drug candidate, Leucettinib 21, has been selected among over 500 synthesized Leucettinibs. Additionally, Perha Pharma is working on a proof-of-concept to prevent hair cell apoptosis of the inner ear in cell models exposed to cisplatin and acoustic trauma. Co-founded by Dr. Laurent MEIJER and Dr. Philippe de LAVENNE in April 2019, Perha Pharma is now preparing for regulatory preclinical studies.